艾拉莫德治疗原发性干燥综合征的多中心随机对照试验
该多中心随机对照试验比较艾拉莫德(IGU)与羟氯喹(HCQ)治疗活动性原发性干燥综合征(pSS)的疗效与安全性。78例患者随机分组,24周时主要终点SSRI-30应答率IGU组57.9%对HCQ组40.0%(p=0.114)无统计学差异,但IGU在STAR和ESSDAI应答率及IgG降低方面显著更优,不良事件多为轻度。
要点
- IGU组SSRI-30主要终点应答率57.9%,HCQ组40.0%,差异无统计学意义(p=0.114)。
- IGU组STAR应答率39.5%显著高于HCQ组15.0%(p=0.015)。
- IGU组ESSDAI应答率21.1%显著高于HCQ组5.0%(p=0.034),且IgG降低更优(p=0.046)。
核心结论
- IGU单药治疗在活动性pSS的复合、系统性和血清学结局方面较HCQ显著改善,且耐受性良好。
- IGU有望成为pSS的治疗选择,尤其适用于高球蛋白血症患者亚组。
研究设计与样本
- 多中心随机对照试验,纳入活动性pSS患者,按1:1随机接受IGU(25 mg每日两次)或HCQ(0.2 g每日两次)治疗24周。
- 共随机78例(HCQ组40例,IGU组38例),66例完成24周研究(HCQ组35例,IGU组31例)。
主要发现
- 主要终点SSRI-30应答率IGU组57.9%对HCQ组40.0%,数值上更高但无统计学显著性(p=0.114)。
- 关键次要终点STAR应答率IGU组39.5%显著高于HCQ组15.0%(p=0.015)。
- ESSDAI应答率IGU组21.1%显著高于HCQ组5.0%(p=0.034)。
- IGU组IgG降低优于HCQ组(p=0.046)。
- 不良事件IGU组更频繁(60.6%对37.8%),但大多为轻度。
关键数值与推荐
- 主要终点为第24周SSRI-30应答率。
- 次要终点包括STAR、ESSDAI、ESSPRI应答率及生物标志物变化。
临床怎么用
- 对于活动性pSS患者,尤其是高球蛋白血症亚组,IGU单药可能较HCQ更有效改善系统性和血清学指标。
- 使用IGU时需关注不良事件,虽多为轻度,但发生率高于HCQ。
局限性
- 主要终点SSRI-30应答率未达统计学显著性。
- 样本量较小(共78例随机),完成研究66例。
- 不良事件在IGU组更频繁。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multicentre randomised controlled trial aimed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren's syndrome (pSS). METHODS: Eligible pSS patients were randomised 1:1 to receive IGU (25 mg two times per day) or HCQ (0.2 g two times per day) for 24 weeks. The primary endpoint was the Sjögren's Syndrome Responder Index-30 (SSRI-30) response rate at week 24. Secondary endpoints included the Sjögren's Tool for Assessing Response (STAR), European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI), EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and biomarker changes. RESULTS: A total of 78 pSS patients were randomised (40 in HCQ group, 38 in IGU group) and 66 patients (35 in HCQ group, 31 in IGU group) completed the 24-week research. SSRI-30 response rate, the primary endpoint, was numerically higher in the IGU group (57.9% vs 40.0%, p=0.114), but with no statistical significance. However, IGU demonstrated significantly higher response rates for key secondary endpoints including STAR (39.5% vs 15.0%, p=0.015) and ESSDAI (21.1% vs 5.0%, p=0.034) response rate. IGU also showed superior IgG reduction (p=0.046). Adverse events were more frequent with IGU (60.6% vs 37.8%) but were mostly mild. CONCLUSION: IGU monotherapy demonstrated significant improvements in composite, systemic and serologic outcomes compared with HCQ in active pSS and was well-tolerated. These findings establish IGU as a promising therapeutic option for pSS, particularly in the subset of patients with hyperglobulinaemia. TRIAL REGISTRATION NUMBER: NCT04981145.
引用
- Chen X, Zhang T, Meng L, et al. Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial. RMD Open. 2025. PMID: 41423293. doi:10.1136/rmdopen-2025-006180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。